Biosimilar Red Tape Elimination Act

United States117th CongressS-6Senate
Updated: Nov 17, 2022

Summary

Biosimilar Red Tape Elimination Act This bill removes and otherwise modifies certain requirements related to the approval of biosimilars, such as prohibiting the Food and Drug Administration from requiring studies that assess the risks of switching between the biosimilar and the reference biologic.

Bill texts

Available versions
Introduced (Senate)View official text

1 version available

All available records shown.

Timeline

  1. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Senate

  2. Introduced in Senate

All available records shown.